Skip to main content
Fig. 5 | Breast Cancer Research

Fig. 5

From: A subgroup of microRNAs defines PTEN-deficient, triple-negative breast cancer patients with poorest prognosis and alterations in RB1, MYC, and Wnt signaling

Fig. 5

PTEN-low plus high Wnt/β-catenin and PI3K signaling or RB1 pathway loss identify TNBC patients with poor clinical outcome. a, b Kaplan-Meier survival curves for PTEN-low plus RB1 signature loss, or high MYC, β-catenin, or PI3K pathway activity in the 205 TNBC training or 44 TNBC validation cohorts. c High β-catenin pathway activity alone does not stratify TNBC into high and low clinical outcome. d Altered expression of genes on the Wnt/β-catenin pathway in PTEN-low/miR-low TNBC (subgroup “a”) compared to subgroup “b,” “c” or PTEN(+) TNBC in the 205 TNBC training cohort

Back to article page